Pulmatrix and Sensory Cloud announced partnership to develop and commercialize nasal prophylactic and anticontagion product for COVID-19

,

On Apr. 16, 2020, Pulmatrix announced a collaboration and license agreement with Sensory Cloud. Under the terms of the Agreement, the Company has granted Sensory Cloud an exclusive, worldwide, royalty bearing license to PUR 003 and PUR 006 (NasoCalm), the Company’s proprietary salt formulations for aerosol nasal administration. The Licensed Products include OTC nasal delivery to potentially reduce the pathogenic risk and transmissibility of contagions, including with respect to COVID-19.

Tags:


Source: Pulmatrix
Credit: